Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Sci Rep
2022 Oct 26;121:17956. doi: 10.1038/s41598-022-22806-9.
Show Gene links
Show Anatomy links
GABAA receptor function is enhanced by Interleukin-10 in human epileptogenic gangliogliomas and its effect is counteracted by Interleukin-1β.
Ruffolo G
,
Alfano V
,
Romagnolo A
,
Zimmer T
,
Mills JD
,
Cifelli P
,
Gaeta A
,
Morano A
,
Anink J
,
Mühlebner A
,
Vezzani A
,
Aronica E
,
Palma E
.
???displayArticle.abstract???
Gangliogliomas (GGs) are low-grade brain tumours that cause intractable focal epilepsy in children and adults. In GG, as in epileptogenic focal malformations (i.e., tuberous sclerosis complex, TSC), there is evidence of sustained neuroinflammation with involvement of the pro-inflammatory cytokine IL-1β. On the other hand, anti-inflammatory mediators are less studied but bear relevance for understanding seizure mechanisms. Therefore, we investigated the effect of the key anti-inflammatory cytokine IL-10 on GABAergic neurotransmission in GG. We assessed the IL-10 dependent signaling by transcriptomic analysis, immunohistochemistry and performed voltage-clamp recordings on Xenopus oocytes microtransplanted with cell membranes from brain specimens, to overcome the limited availability of acute GG slices. We report that IL-10-related mRNAs were up-regulated in GG and slightly in TSC. Moreover, we found IL-10 receptors are expressed by neurons and astroglia. Furthermore, GABA currents were potentiated significantly by IL-10 in GG. This effect was time and dose-dependent and inhibited by blockade of IL-10 signaling. Notably, in the same tissue, IL-1β reduced GABA current amplitude and prevented the IL-10 effect. These results suggest that in epileptogenic tissue, pro-inflammatory mechanisms of hyperexcitability prevail over key anti-inflammatory pathways enhancing GABAergic inhibition. Hence, boosting the effects of specific anti-inflammatory molecules could resolve inflammation and reduce intractable seizures.
Figure 1. Expression of genes of interest in controls, GG and TSC. RNAseq data indicate significant up-regulation (adjusted p value = 0.05) of IL-10Rα, IL-10Rβ, IL-1Ra, IL-1β and STAT3 in both GG and TSC. In addition, there is a significant upregulation of IL-10 and JAK1 in GG. IL-10 downstream signaling protein such as TIK1, phosphokinases (PIK3CA, PIK3CB, PIK3CD) and IL1-R1 did not show significant changes in either GG or TSC vs controls. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. A linear model was fit for each gene and moderated t-statistic was calculated after applying an empirical Bayes smoothing to the standard errors. Those genes with a Benjamini–Hochberg adjusted p value < 0.05 were considered significant. Differential expression analysis compared 21 TSC patients and 15 matched control cortices; 37 GG patients and 15 matched controls cortices.
Figure 2. Cellular expression pattern of IL-10 receptor in GG and TSC. Representative photomicrographs of immunocytochemical staining for IL-10Rα. Sections are counterstained with haematoxylin. Panels (A–C): IL-10Rα immunoreactivity (IR) in control brain. No detectable neuronal or glial labelling is observed in normal cortex (A–B; arrows indicate neurons) and white matter (C). Panels (D–E): IL-10Rα in gangliogliomas (GG). IL-10Rα IR was observed in dysplastic neurons (arrows, D and insert-a in E); insert in D shows expression of IL-10Rα (green) in a NeuN positive (red) dysplastic neuron; insert-b in E shows co-localization of IL-10Rα (blue) with pJAK (red). IL-10Rα IR was observed in scattered astroglial cells (arrowheads in E); insert-c in E shows co-localization of IL-10Rα (green) with GFAP (red). Panels (F–H): IL-10Rα in tuberous sclerosis complex (TSC). IL-10Rα IR was observed in dysmorphic neurons (arrows and inserts in F and H); IR was also observed in astrocytes (arrowheads; insert in H-a) and few giant cells (asterisks) within the dysplastic area. Insert in (F) shows expression of IL-10Rα (green) in a NeuN positive (red) dysmorphic neuron. Insert in (G) shows co-localization of IL-10Rα (green) with MAP2 (red). Insert (a) in (H) shows co-localization of IL-10Rα (green) with GFAP (red). Insert (b) in (H) shows co-localization of IL-10Rα (blue) with pS6 (red) in a dysmorphic neuron. Scale bar: (A, D): 100 µm; (F, G): 80 µm; (B, C, E): 40 µm; (H): 30 µm. Details on the cohort used are reported in Supplementary Information.
Figure 3. IL-10 effect on GABA current amplitude in oocytes injected with human α1β2γ2 cDNA. The bar-graph represents the mean and ± s.e.m. of the IGABA amplitudes evoked from oocytes intranuclearly injected with α1β2γ2 cDNAs before (black) and after (red) the incubation with IL-10 (200 ng/mL, 3 h; n = 8; p > 0.05 by paired t-test).The IGABA amplitudes recorded after the IL-10 incubation were normalized to the response obtained before exposure to IL-10 for each cell (range of current amplitudes: from 247.5 to 1119.0 nA), then averaged and expressed as a percent variation. Traces depict representative currents measured after 4 s application of GABA (white bar, 50 μM) in oocytes injected with α1β2γ2 cDNAs before (black trace) and after (red trace) IL-10 incubation (for 3 h). Grey bar on the right trace represents the block by 100 μM bicuculline (representative of 4 experiments).
Figure 4. Time-course effect of IL-10 on GABA current amplitude in oocytes microinjected with GG tissue. GABA alone was applied at 250 μM at the beginning of each experiment (time zero) and at various time points after treatment with 100 ng/ml IL-10. Data (mean ± s.e.m.; n = 6–12 oocytes/time point; patients #8–12 in Table 1) represent the percentage increase of the peak amplitude induced by IL-10. Data were normalized to the mean current amplitude recorded at time zero (23.7 ± 8.6 nA, n = 12). Inset: Traces depict representative GABA currents at the indicated times. * = p < 0.05 by Wilcoxon signed rank test; ** = p < 0.01 by paired t-test.
Figure 5. Characterization and blockade of IL-10 effect on GABA current amplitude. (A) Bar-graph of IL-10 effect on IGABA current amplitude in oocytes microtransplanted with control tissue (n = 17), TSC (n = 24) and GG (n = 80) tissues. Data are expressed as mean ± s.e.m. Inset: IGABA amplitude is expressed as percent increase above baseline (before IL-10 incubation, ranges of current amplitudes: control tissue, from 3.8 to 53.7 nA; TSC, from 7.7 to 73.7 nA; GG, from 5.5 to 84.0 nA). ** = p < 0.01 by paired t-test. (B) Representative superimposed current traces (GABA 250 μM, white bars) of control-, TSC- and GG-injected oocytes before (black trace) and after (red trace) incubation with IL-10 (100 ng/mL for 3 h). Grey bars represent the block by 100 μM bicuculline (representative of 3 experiments for each tissue) (C) Bar-graph shows the effect of incubation of K252a (2 μM, a broad-spectrum protein kinases inhibitor) or baricitinib (Bar 0.5 μM, a selective JAK1 and JAK2 inhibitor) with IL-10 (100 ng/ml). Black bar-graph represents the mean current value (nA) before incubation with IL-10 alone (red, n = 18) or in combination with the two blockers (blue, n = 8 for each blocker). ** = p < 0.01 by paired t-test (D) Dose–response curves of GABA (1 μM–1 mM) before (black curve) and after (red curve) incubation with IL-10 (100 ng/ml for 3 h) in oocytes microinjected with GG tissues (Patients # 8–10, Table 1). Averaged EC50 were 107.0 ± 9.7 μM, nH = 1.4 ± 0.10, before IL-10 and 67.0 ± 3.79 μM, nH = 1.77 ± 0.16; n = 16; statistics for the dose–response experiments: p < 0.05 by paired t-test.
Figure 6. Effect of IL-1β on GABA current in the absence or presence of IL-10. Bar-graphs show the % variation in IGABA amplitude induced by IL-10 (red bar and trace), IL-1β (green bar and trace) or their combination (grey bar and trace) in oocytes injected with GG tissues (Patients # 8–10; Table 1). Data are expressed as a % variation of the mean current amplitude after the incubation with each cytokine singularly or in combination. Mean current variation was + 31.0 ± 2.6% after IL-10 incubation (100 ng/ml, n = 10), − 19.6 ± 3.15% after incubation with IL-1β (25 ng/ml, n = 10) and − 15.6 ± 3.5% after co-incubation with IL-10 + IL-1β (n = 10) as described in the text. ** p < 0.01 by paired t-test.
Ambrogini,
Neurobiological Correlates of Alpha-Tocopherol Antiepileptogenic Effects and MicroRNA Expression Modulation in a Rat Model of Kainate-Induced Seizures.
2018, Pubmed,
Xenbase
Ambrogini,
Neurobiological Correlates of Alpha-Tocopherol Antiepileptogenic Effects and MicroRNA Expression Modulation in a Rat Model of Kainate-Induced Seizures.
2018,
Pubmed
,
Xenbase
Aronica,
Gene expression profile analysis of epilepsy-associated gangliogliomas.
2008,
Pubmed
Bartfai,
Interleukin-1 system in CNS stress: seizures, fever, and neurotrauma.
2007,
Pubmed
Basnyat,
Chronically reduced IL-10 plasma levels are associated with hippocampal sclerosis in temporal lobe epilepsy patients.
2020,
Pubmed
Blumcke,
Neocortical development and epilepsy: insights from focal cortical dysplasia and brain tumours.
2021,
Pubmed
Blümcke,
Review: Challenges in the histopathological classification of ganglioglioma and DNT: microscopic agreement studies and a preliminary genotype-phenotype analysis.
2019,
Pubmed
Brandon,
GABAA receptor phosphorylation and functional modulation in cortical neurons by a protein kinase C-dependent pathway.
2000,
Pubmed
Brooks-Kayal,
Selective changes in single cell GABA(A) receptor subunit expression and function in temporal lobe epilepsy.
1998,
Pubmed
Cases-Cunillera,
Heterogeneity and excitability of BRAFV600E-induced tumors is determined by Akt/mTOR-signaling state and Trp53-loss.
2022,
Pubmed
Chamberlain,
Interleukin-10 and Small Molecule SHIP1 Allosteric Regulators Trigger Anti-inflammatory Effects through SHIP1/STAT3 Complexes.
2020,
Pubmed
Chuang,
Genetic and Molecular Regulation of Extrasynaptic GABA-A Receptors in the Brain: Therapeutic Insights for Epilepsy.
2018,
Pubmed
Cifelli,
Dissecting the Molecular Determinants of GABAA Receptors Current Rundown, a Hallmark of Refractory Human Epilepsy.
2021,
Pubmed
,
Xenbase
Conti,
Anomalous levels of Cl- transporters cause a decrease of GABAergic inhibition in human peritumoral epileptic cortex.
2011,
Pubmed
,
Xenbase
Curatolo,
Advances in the genetics and neuropathology of tuberous sclerosis complex: edging closer to targeted therapy.
2022,
Pubmed
Ertürk Çetin,
Epilepsy-related brain tumors.
2017,
Pubmed
Farrant,
Variations on an inhibitory theme: phasic and tonic activation of GABA(A) receptors.
2005,
Pubmed
Gallentine,
Plasma cytokines associated with febrile status epilepticus in children: A potential biomarker for acute hippocampal injury.
2017,
Pubmed
Goz,
BRAFV600E expression in neural progenitors results in a hyperexcitable phenotype in neocortical pyramidal neurons.
2020,
Pubmed
Gruber,
Impaired myelin production due to an intrinsic failure of oligodendrocytes in mTORpathies.
2021,
Pubmed
Hulkkonen,
The balance of inhibitory and excitatory cytokines is differently regulated in vivo and in vitro among therapy resistant epilepsy patients.
2004,
Pubmed
Kenney-Jung,
Febrile infection-related epilepsy syndrome treated with anakinra.
2016,
Pubmed
Kim,
Analysis of plasma multiplex cytokines and increased level of IL-10 and IL-1Ra cytokines in febrile seizures.
2017,
Pubmed
Koh,
BRAF somatic mutation contributes to intrinsic epileptogenicity in pediatric brain tumors.
2018,
Pubmed
Korotkov,
Down-regulation of the brain-specific cell-adhesion molecule contactin-3 in tuberous sclerosis complex during the early postnatal period.
2022,
Pubmed
Lai,
Anakinra usage in febrile infection related epilepsy syndrome: an international cohort.
2020,
Pubmed
Louis,
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.
2021,
Pubmed
Maroso,
Interleukin-1β biosynthesis inhibition reduces acute seizures and drug resistant chronic epileptic activity in mice.
2011,
Pubmed
Miledi,
Microtransplantation of neurotransmitter receptors from cells to Xenopus oocyte membranes: new procedure for ion channel studies.
2006,
Pubmed
,
Xenbase
Mills,
Coding and non-coding transcriptome of mesial temporal lobe epilepsy: Critical role of small non-coding RNAs.
2020,
Pubmed
Moore,
Interleukin-10 and the interleukin-10 receptor.
2001,
Pubmed
Morin-Brureau,
Microglial phenotypes in the human epileptic temporal lobe.
2018,
Pubmed
Müller,
Astrocytic GABA Accumulation in Experimental Temporal Lobe Epilepsy.
2020,
Pubmed
Noe,
Pharmacological blockade of IL-1β/IL-1 receptor type 1 axis during epileptogenesis provides neuroprotection in two rat models of temporal lobe epilepsy.
2013,
Pubmed
Northrup,
Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations.
2021,
Pubmed
Oto,
Plasma proinflammatory and anti-inflammatory cytokine and catecholamine concentrations as predictors of neurological outcome in acute stroke patients.
2008,
Pubmed
Pallud,
Cortical GABAergic excitation contributes to epileptic activities around human glioma.
2014,
Pubmed
Palma,
Microtransplantation of membranes from cultured cells to Xenopus oocytes: a method to study neurotransmitter receptors embedded in native lipids.
2003,
Pubmed
,
Xenbase
Palma,
Phosphatase inhibitors remove the run-down of gamma-aminobutyric acid type A receptors in the human epileptic brain.
2004,
Pubmed
,
Xenbase
Palma,
The antiepileptic drug levetiracetam stabilizes the human epileptic GABAA receptors upon repetitive activation.
2007,
Pubmed
,
Xenbase
Palma,
Expression of human epileptic temporal lobe neurotransmitter receptors in Xenopus oocytes: An innovative approach to study epilepsy.
2002,
Pubmed
,
Xenbase
Porro,
The Regulatory Role of IL-10 in Neurodegenerative Diseases.
2020,
Pubmed
Prabowo,
BRAF V600E mutation is associated with mTOR signaling activation in glioneuronal tumors.
2014,
Pubmed
Prabowo,
Differential expression and clinical significance of three inflammation-related microRNAs in gangliogliomas.
2015,
Pubmed
Prabowo,
Differential expression of major histocompatibility complex class I in developmental glioneuronal lesions.
2013,
Pubmed
Ragozzino,
Rundown of GABA type A receptors is a dysfunction associated with human drug-resistant mesial temporal lobe epilepsy.
2005,
Pubmed
,
Xenbase
Ravizza,
The IL-1beta system in epilepsy-associated malformations of cortical development.
2006,
Pubmed
Roseti,
GABAA currents are decreased by IL-1β in epileptogenic tissue of patients with temporal lobe epilepsy: implications for ictogenesis.
2015,
Pubmed
,
Xenbase
Roseti,
Fractalkine/CX3CL1 modulates GABAA currents in human temporal lobe epilepsy.
2013,
Pubmed
,
Xenbase
Roskoski,
Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
2016,
Pubmed
Ruffolo,
Functional aspects of early brain development are preserved in tuberous sclerosis complex (TSC) epileptogenic lesions.
2016,
Pubmed
,
Xenbase
Ruffolo,
A novel action of lacosamide on GABAA currents sets the ground for a synergic interaction with levetiracetam in treatment of epilepsy.
2018,
Pubmed
,
Xenbase
Saraiva,
The regulation of IL-10 production by immune cells.
2010,
Pubmed
Scalise,
Human iPSC Modeling of Genetic Febrile Seizure Reveals Aberrant Molecular and Physiological Features Underlying an Impaired Neuronal Activity.
2022,
Pubmed
,
Xenbase
Slegers,
Low-grade developmental and epilepsy associated brain tumors: a critical update 2020.
2020,
Pubmed
Specchio,
Surgery for drug-resistant tuberous sclerosis complex-associated epilepsy: who, when, and what.
2021,
Pubmed
Stellwagen,
Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factor-alpha.
2005,
Pubmed
Sun,
Interleukin-10 inhibits interleukin-1β production and inflammasome activation of microglia in epileptic seizures.
2019,
Pubmed
Suryanarayanan,
Role of interleukin-10 (IL-10) in regulation of GABAergic transmission and acute response to ethanol.
2016,
Pubmed
Tamura,
K252a, an inhibitor of Trk, disturbs pathfinding of hippocampal mossy fibers.
2006,
Pubmed
Vezzani,
Neuroinflammatory pathways as treatment targets and biomarkers in epilepsy.
2019,
Pubmed
Vezzani,
Epilepsy and brain inflammation.
2013,
Pubmed
Vezzani,
Neuromodulatory properties of inflammatory cytokines and their impact on neuronal excitability.
2015,
Pubmed
Wong,
Mechanisms of epileptogenesis in tuberous sclerosis complex and related malformations of cortical development with abnormal glioneuronal proliferation.
2008,
Pubmed
Zhang,
Interleukin-10 Attenuates Behavioral, Immune and Neurotrophin Changes Induced by Chronic Central Administration of Interleukin-1β in Rats.
2022,
Pubmed
Zhang,
Inflammatory mechanisms contribute to the neurological manifestations of tuberous sclerosis complex.
2015,
Pubmed
de Vries,
Inflammatory mediators in human epilepsy: A systematic review and meta-analysis.
2016,
Pubmed
